Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 2

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 2
---
 and non-voting outstanding common stock held by non-affiliates was approximately $ 3.0billion based upon the closing stock price of issuer’s common stock on March 31, 2024. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of November 20, 2024, 124,434,442shares of the issuer’s Common Stock were issued and outstanding.

### DOCUMENTS INCORPORATED BY REFERENCE
None.

### EXPLANATORY NOTE
Arrowhead Pharmaceuticals, Inc. (the “Company” or “Arrowhead”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to its Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024 (the “Original Report”) solely to include the information required by Items 10 through 14 of Part III of Form 10-K (the “Part III Information”) not included in the Original Report in order to comply with General Instruction G.3 of Form 10-K. The Company’s Definitive Proxy Statement on Schedule 14A containing the Part III Information was filed with the SEC on January 29, 2025 (the “Proxy Statement”) was filed three minutes after the filing deadline on the 120th day after the Company’s fiscal year end. Except as noted below, the Part III Information included in this Amendment is as of January 28, 2025.

Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith. Because no financial statements have been included in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.